Long-term survival with anlotinib as a front-line treatment in an elderly NSCLC patient: A case report

作者全名："Wang, Jingyi; Li, Xiaoqing; Zhou, Juan; Qiu, Dan; Zhang, Mengyao; Sun, Lan; Li, Shengwen Calvin"

作者地址："[Wang, Jingyi; Li, Xiaoqing; Zhou, Juan; Qiu, Dan; Zhang, Mengyao; Sun, Lan] Chongqing Med Univ, Bishan Hosp, Dept Oncol, Chongqing, Peoples R China; [Li, Shengwen Calvin] Childrens Hosp Orange Cty CHOC, CHOC Childrens Res Inst, Ctr Neurosci Res, Neurooncol & Stem Cell Res Lab, Orange, CA 92868 USA; [Li, Shengwen Calvin] Univ Calif Irvine, Sch Med, Dept Neurol, Orange, CA 92617 USA"

通信作者："Sun, L (通讯作者)，Chongqing Med Univ, Bishan Hosp, Dept Oncol, Chongqing, Peoples R China.; Li, SWC (通讯作者)，Childrens Hosp Orange Cty CHOC, CHOC Childrens Res Inst, Ctr Neurosci Res, Neurooncol & Stem Cell Res Lab, Orange, CA 92868 USA.; Li, SWC (通讯作者)，Univ Calif Irvine, Sch Med, Dept Neurol, Orange, CA 92617 USA."

来源：FRONTIERS IN ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000971479600001

JCR分区：Q2

影响因子：4.7

年份：2023

卷号：13

期号：　

开始页：　

结束页：　

文献类型：Article

关键词：non-small cell lung cancer; anti-angiogenesis therapy; front-line treatment; elderly patients; case report; Anlotinib hydrochloride; tegafur-uracil; chemotherapy

摘要："BackgroundHalf of the population of non-small cell lung cancer (NSCLC) patients are older than 70 years and have limited therapeutic options due to poor tolerance and being excluded in most clinical trials. Anlotinib hydrochloride, a novel oral multi-target tyrosine kinase inhibitor, has been approved for the standard third-line treatment for NSCLC in China. Herein we report an elderly NSCLC patient without any driver gene mutations who was undergoing anlotinib as a front-line treatment and who achieved long-term survival. Case summaryThe 77-year-old male patient was admitted to the hospital for chest tightness after engaging in physical activity for a week. The patient has been diagnosed with stage IIIB driver gene-negative squamous cell lung carcinoma. After that, he was treated with anlotinib for 2 years and 10 months from the first diagnosis until the last disease progression. Briefly, anlotinib combined with platinum-based chemotherapy was performed as the first-line therapy over six cycles. After 6 more cycles of anlotinib monotherapy maintenance, disease progression occurred. Then, anlotinib combined with tegafur was administered as a salvage treatment, and the disease was controlled again. After 29 cycles of anlotinib combined with tegafur regimens, the disease progressed finally. The patient achieved a total of 34 months of progression-free survival after anlotinib was used as the front-line treatment. He is still alive with a good performance status now (performance status score: 1). ConclusionThis patient achieved long-term survival using anlotinib as a front-line regimen combined with chemotherapy."

基金机构：　

基金资助正文：